Expert support teamAgilent offers your lab a wide range of support tools to support you from the initial set-up and day-to-day management to the continuous improvement of your operations. All to ensure that you get off on a good start with the MASTR assays. Agilent trains your collaborators and does not stop until everything is running smoothly. We can also help you select the right equipment and optimize your workflow and experts are always at your disposition. Furthermore, the online tools help you calculate the number of samples to be pooled per run amongst others. Agilent guides your lab towards reliable results. Every step of the way.

Learn more: www.agilent.com

U.S. and Canada 1-800-227-9770 agilent_inquiries@agilent.com

Asia Pacific inquiry_lsca@agilent.com

5 genes (SNV+CNV)

Hypertrophic Cardiomyopathy (HCM) is the most common inherited cardiovascular disease. It is estimated to affect as many as 1 in 500 people and is the leading cause of sudden cardiac death in young adults. HCM occurs when the heart muscle cells enlarge causing the walls of the ventricles to thicken and block out blood flow in the ventricles, causing the ventricle walls to stiffen resulting in a reduced ability of the heart to contract.

Benefits: – Ready-to-use & robust design: targeted gene panel increases the efficiency of

your workflow by allowing more samples per run and resulting in faster results.

– In depth data analysis: allows SNV, CNV and indel calling.

– Simple workflow: easy implementation of the MASTR Assays.

HCM MASTR for Early Detection of Mutations Associated with Hypertrophic Cardiomyopathy (HCM)

“HCM MASTR facilitates robust and rapid sequencing of the 5 major HCM genes with high sensitivity.”

– Dr. Pascale Richard, Hôpital Pitié Salpêtrière in Paris, France

www.agilent.com

For Research Use Only. Not for use in diagnostic procedures.

PR7000-1965 © Agilent Technologies, Inc. 2018 Published in the USA, June, 2018 5991-9349EN

MASTR Assays: Amplicon-Based Solutions for CardiologySequence the genes that matter

Agilent offers a comprehensive range of targeted amplicon-based solutions for cardio genetics. All MASTR assays focus on the genes that are clinically relevant. Using a targeted gene assay increases the efficiency of your workflow by allowing you to perform more samples per run. The unique amplicon amplification PCR technique of the MASTR assays makes your test results more accurate and increases the reliability of your routine testing. The assays’ simple-to-follow protocols for different NGS systems reduces the time and effort needed to process the samples and enables your laboratory to perform testing on a large scale.

Next-Generation Sequencing. Focus on the Genes that Matter.

MASTR Assays for genes associated with Sudden Cardiac Arrest

As a leading cause of mortality, Sudden Cardiac Death (SCD) affects one in a thousand people in Western countries. It can be caused by various syndromes associated with ADH, PED and HCM. As most inherited cardiac diseases show an autosomal dominant pattern of inheritance, relatives of young SCD have 50 % risk of carrying the inherited predisposition to develop cardiac disease.

Current methods, such as High-Resolution Melting and Sanger sequencing, are time consuming, labor-intensive and expensive. Therefore, Agilent created three ready-to-use Research MASTR assays to identify variants by NGS to provide a simple, fast and cost-effective approach. Three trusted Cardio solutions to provide your lab with rapid and reliable results.

4 genes (SNV+CNV) & 12 predisposing SNPs (1)

Autosomal dominant familial hypercholesterolemia (ADH) is a genetic disorder characterized by mutations in LDLR, PCSK9, APOB and APOE variants and by substantially raised levels of low-density lipoprotein cholesterol (LDL-C). Its prevalence is reported to be 1:500 in the general population, but this may be underestimated as higher frequencies have been reported for certain populations. However, in about 60% of patients, causative mutations in these genes are absent. In these patients, raised LDL-C concentrations may have a polygenic cause.

Benefits: – Clinically relevant genes: covers the 4 clinically relevant genes mentioned by the

reference criteria of Simone Broome and the Dutch Lipid Network for ADH.

– Unique targeted panel: sequences only the genes that matter, allowing fast and reliable results.

– 12 Cholesterol raising SNPs: allow detection of polygenic causes of ADH.

ADH MASTR v2 for Identification of Mutations Associated with Monogenic and Polygenic Familiar Hypercholesterolemia (FH)

“The ADH MASTR v2 assay is an efficient, easy to implement and cost effective NGS tool allowing the detection of monogenic and polygenic forms of Familial Hypercholesterolemia.”

– Dr. Alain Carrié, Hôpital Pitié Salpêtrière and University Pierre and Marie Curie in Paris, France

51 genes (SNV)

Primary Electrical Disorders (PED) cause arrhythmias and have, unlike other causes of Sudden Cardiac Arrest, different electrocardiographical patterns which are difficult to detect. Molecular genetic screening can reveal these specific mutations of ion channels and can identify the difficult to detect functional defects.

Benefits: – Robust design: targeted gene panel resulting in faster results.

– Professional expertise: developed in collaboration with key opinion leaders.

– Continuous support: guiding your lab towards reliable results every step of the way and easy implementation of the MASTR Assays.

PED MASTR PLUS for Identification of Mutations Associated with Primary Electrical Disorders (PED) Predisposing to Arrhythmias

“PED MASTR Plus assay is a proficient, highly reliable and reproducible technique to use in routine to screen for genes associated with primary hereditary arrhythmias.”

– Prof. Dr. Bart Loeys, Antwerp University Hospital, Belgium